Latest Regulatory News

The Takeovers Panel has decided not to proceed with an application challenging Keybridge Capital’s board decisions amid Yowie Group’s takeover bid, citing prior rulings and no unacceptable circumstances.

Australian Strategic Materials unveils a transformative heap leach approach for its Dubbo Project, cutting upfront capital costs by over half and accelerating rare earth oxide production amid rising global demand.

BMG Resources has addressed ASX concerns over the timing and disclosure of assay results from its Abercromby Gold Project drill program, confirming compliance with listing rules despite delays and data inconsistencies.

The Takeovers Panel has mandated Emu NL to hold a new shareholder meeting after finding serious irregularities in the recent extraordinary general meeting, including share issuance timing and proxy voting issues.

Mithril Silver and Gold Limited has arranged a placement to raise up to C$11.5 million, aiming to accelerate exploration at its Copalquin project in Mexico’s prolific Sierra Madre Trend.

Tissue Repair Limited has secured major distribution partnerships in Australia, New Zealand, and Thailand for its TR Pro+® product line, marking a pivotal shift from development to commercialisation. The company is also scaling up manufacturing and advancing regulatory approvals to support its global expansion ambitions.

Environmental Clean Technologies Limited (ECT) plans a 15-to-1 capital consolidation to streamline its share structure and attract broader investor interest, pending shareholder approval in August 2025.

Almonty Industries has had its trading suspension lifted following the release of an updated technical report on its Sangdong Project in South Korea, signaling renewed investor access and potential project reassessment.

Red Mountain Mining reports promising gold assays at Oaky Creek and announces a fully funded trenching and soil sampling program to advance its Armidale Antimony-Gold project.

Invion Limited’s IVXO securities have been suspended from ASX quotation due to non-compliance with key listing rules, raising questions about the company’s regulatory standing and investor confidence.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing of Elate Ocular, a promising treatment for moderate to severe dry eye disease, pending additional financing.

Pharmx Technologies has extended its pivotal National Diabetes Services Scheme agreement and expanded its supplier base, reinforcing its leadership in pharmacy digital infrastructure across Australia and New Zealand.